Under the new agreement, Fenwal will supply Cerus with finished disposable kits for the Intercept platelet and plasma systems through the end of 2013.
Claes Glassell, president and CEO of Cerus, said: “We are pleased to have extended our supply relationship with Fenwal. The new agreement is expected to assure our long-term supply of finished Intercept platelet and plasma kits while reducing our unit costs.
“Together with other initiatives, we believe we are making good progress toward meeting our objective of extending our cash resources through the end of 2009.”